|
Celtek has developed a highly effective, patent-pending peptide
agent (CB5005) that shows specific activity in promoting significant levels of apoptosis of androgen-independent prostate
cancer cells, either alone or in combination with conventional chemotherapeutic drugs, such as cisplatin or etoposide.
CB5005,
by virtue of its mechanism of action, also has other therapeutic uses. Celtek is currently investigating the various therapeutic
uses for CB5005 and is actively developing it as a therapeutic agent for the treatment of cancer and other human diseases.
CB5005’s first target is androgen-independent prostate cancer, prostate cancer being the second leading cause of cancer-related
deaths in the United States.
The company has successfully obtained funding for its research and development activities
from the National Institutes of Health. Celtek welcomes capital investment and joint development partnerships to obtain FDA
approval of CB5005 and market the product for its many uses, starting with prostate cancer therapy.
In addition to
CB5005, Celtek team is also working on R&D of other cell-permeable peptide-based preclinical drug compounds, which may be
therapeutically effective for a variety of human diseases.
|
